OBJECTIVE: Allosensitization of left ventricular assist device recipients has been associated with perioperative transfusion of cellular blood products. The relative sensitizing contribution of leukofiltered cellular blood products, however, remains unclear. We investigated the pattern of sensitization in left ventricular assist device recipients in relation to cellular blood product transfusions received. METHODS: Seventy-one consecutive nonsensitized recipients of the HeartMate left ventricular assist device (Thoratec Corporation, Pleasanton, Calif) as a bridge to transplantation were reviewed. Panel-reactive HLA antibody levels at consecutive times after device implantation were correlated with perioperative cellular blood product transfusions. RESULTS: Fifty-four patients received leukofiltered cellular blood products (transfused), whereas 17 patients received only fresh-frozen plasma (nontransfused). Among nontransfused patients, 58.8% (10/17) became sensitized during mechanical support, versus 35.2% of transfused patients (19/54, P = .15). There was a trend toward more sensitization during the 12 weeks after device placement in nontransfused patients. Kaplan-Meier analysis revealed significantly more sensitization in nontransfused patients than in transfused patients, despite equal rates of transplantation (P = .05). A dose-response analysis revealed significant trends toward less sensitization and lower peak panel-reactive antibody level with more cellular blood product transfusions (P = .04). Multivariate Cox regression revealed only increasing transfusions to be associated with a reduced risk of sensitization (hazard ratio 0.18, P = .01). CONCLUSIONS: Sensitization becomes more prevalent with increasing length of support. Avoidance of perioperative leukocyte-filtered cellular blood product transfusions does not decrease the incidence or degree of HLA sensitization. Conversely, cellular blood product transfusions may be associated with lessened alloimmunization and may mitigate the sensitization seen in recipients of the HeartMate left ventricular assist device as a bridge to transplantation.
OBJECTIVE: Allosensitization of left ventricular assist device recipients has been associated with perioperative transfusion of cellular blood products. The relative sensitizing contribution of leukofiltered cellular blood products, however, remains unclear. We investigated the pattern of sensitization in left ventricular assist device recipients in relation to cellular blood product transfusions received. METHODS: Seventy-one consecutive nonsensitized recipients of the HeartMate left ventricular assist device (Thoratec Corporation, Pleasanton, Calif) as a bridge to transplantation were reviewed. Panel-reactive HLA antibody levels at consecutive times after device implantation were correlated with perioperative cellular blood product transfusions. RESULTS: Fifty-four patients received leukofiltered cellular blood products (transfused), whereas 17 patients received only fresh-frozen plasma (nontransfused). Among nontransfused patients, 58.8% (10/17) became sensitized during mechanical support, versus 35.2% of transfused patients (19/54, P = .15). There was a trend toward more sensitization during the 12 weeks after device placement in nontransfused patients. Kaplan-Meier analysis revealed significantly more sensitization in nontransfused patients than in transfused patients, despite equal rates of transplantation (P = .05). A dose-response analysis revealed significant trends toward less sensitization and lower peak panel-reactive antibody level with more cellular blood product transfusions (P = .04). Multivariate Cox regression revealed only increasing transfusions to be associated with a reduced risk of sensitization (hazard ratio 0.18, P = .01). CONCLUSIONS: Sensitization becomes more prevalent with increasing length of support. Avoidance of perioperative leukocyte-filtered cellular blood product transfusions does not decrease the incidence or degree of HLA sensitization. Conversely, cellular blood product transfusions may be associated with lessened alloimmunization and may mitigate the sensitization seen in recipients of the HeartMate left ventricular assist device as a bridge to transplantation.
Authors: O Wever-Pinzon; J Stehlik; A G Kfoury; J V Terrovitis; N A Diakos; C Charitos; D Y Li; S G Drakos Journal: Pharmacol Ther Date: 2012-01-16 Impact factor: 12.310
Authors: Matthew L Stone; Damien J LaPar; Ehsan Benrashid; David C Scalzo; Gorav Ailawadi; Irving L Kron; James D Bergin; Randal S Blank; John A Kern Journal: J Card Surg Date: 2014-12-21 Impact factor: 1.620
Authors: Peter Chiu; Justin M Schaffer; Philip E Oyer; Michael Pham; Dipanjan Banerjee; Y Joseph Woo; Richard Ha Journal: J Heart Lung Transplant Date: 2016-01-07 Impact factor: 10.247
Authors: Murray H Kwon; Jennifer Q Zhang; Joanna M Schaenman; Martin Cadeiras; David W Gjertson; Carolyn A Krystal; Hillel Laks; Abbas Ardehali; Mario C Deng; Richard J Shemin; Elaine F Reed Journal: J Thorac Cardiovasc Surg Date: 2015-01-08 Impact factor: 5.209
Authors: Anthony W Castleberry; Adam D DeVore; Kevin W Southerland; James M Meza; William D Irish; Joseph G Rogers; Carmelo A Milano; Chetan B Patel Journal: ASAIO J Date: 2016 May-Jun Impact factor: 2.872
Authors: Stavros G Drakos; Abdallah G Kfoury; John R Kotter; Bruce B Reid; Stephen E Clayson; Craig H Selzman; Josef Stehlik; Patrick W Fisher; Mario Merida; David D Eckels; Kim Brunisholz; Benjamin D Horne; Sandi Stoker; Dean Y Li; Dale G Renlund Journal: J Heart Lung Transplant Date: 2009-08 Impact factor: 10.247